3 Biotech Firms With Major Potential Catalysts in the Coming Months

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.

MarketBeat • 7 hours ago

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.

The Motley Fool • Jun 18, 2026

Is the Options Market Predicting a Spike in Krystal Biotech Stock?

Investors need to pay close attention to KRYS stock based on the movements in the options market lately.

Zacks Investment Research • Jun 5, 2026

Krystal Biotech Stock Soars 16% in Three Months: Here's Why

KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.

Zacks Investment Research • Jun 4, 2026

Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 3, 2026

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • May 26, 2026

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m.

GlobeNewsWire • May 21, 2026

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan  VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB PITTSBURGH, May 18, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that, on May 15, 2026, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth. VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB and is designed to address the root cause of the disease by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing.

GlobeNewsWire • May 18, 2026

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

This Profitable Biotech Stealthily Climbs Into A Buy Zone

This genetic disorder treatment developer's stock hit a buy point after the biotech's first-quarter earnings report last week.

Investors Business Daily • May 11, 2026